---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-052029"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:27:03.736163+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose

## Summary
- Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.
- VisiRose is a majority-owned subsidiary focused on developing rose bengal sodium for ophthalmology diseases and disorders.
- University of Miami approved assignment and novation, releasing Provectus from future obligations under the license.
- Provectus grants VisiRose a non-exclusive, worldwide, royalty-free license to Licensee Background IP as needed.
- Agreement reflects Provectus's strategy to separate ophthalmic assets into a dedicated subsidiary.

## SEC filing metadata
- accession: 0001493152-24-052029
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/0001493152-24-052029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-052029
- JSON: https://secwatch.observer/filing/0001493152-24-052029.json
- Plain text: https://secwatch.observer/filing/0001493152-24-052029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.